Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Altimmune Inc (NQ: ALT ) 6.940 +0.180 (+2.66%) Streaming Delayed Price Updated: 4:00 PM EDT, Aug 23, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 2,143,975 Open 6.810 Bid (Size) 6.890 (4) Ask (Size) 6.950 (1) Prev. Close 6.760 Today's Range 6.660 - 7.025 52wk Range 2.090 - 14.84 Shares Outstanding 71,070,951 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Decoding 4 Analyst Evaluations For Altimmune August 22, 2024 Via Benzinga 3 Promising Biotech Stocks for the Long-Term: August 2024 August 13, 2024 Some of the best biotech opportunities can be found in oversold obesity treatment stocks. Here are just a few. Via InvestorPlace Performance YTD -34.03% -34.03% 1 Month +3.74% +3.74% 3 Month -0.43% -0.43% 6 Month -38.69% -38.69% 1 Year +189.17% +189.17% More News Read More The 7 Best Under $10 Stocks to Buy in August 2024 August 11, 2024 Via InvestorPlace Prediction: This Weight Loss Stock Will Be Acquired Within the Next Year August 09, 2024 Via The Motley Fool ALT Stock Earnings: Altimmune Misses EPS for Q2 2024 August 08, 2024 Via InvestorPlace CytoSorbents to Report Second Quarter 2024 Operating and Financial Results August 07, 2024 From CytoSorbents Via GlobeNewswire Are Eli Lilly and Novo Nordisk Too Expensive For You? Here Are 4 Other Potential Weight Loss Stocks You May Want to Consider Right Now. August 02, 2024 Via The Motley Fool ALTIMMUNE ALERT: Bragar Eagel & Squire, P.C. is Investigating Altimmune, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm July 30, 2024 From Bragar Eagel & Squire Via GlobeNewswire Can These 2 Biotechs Beat Eli Lilly and Novo Nordisk in Weight-Loss Drugs? July 20, 2024 Via The Motley Fool 3 Undervalued Biotech Stocks With Breakout Potential July 19, 2024 Via InvestorPlace Forget Boring Diversification! 3 Wild-Card Stocks to Spice Up Your Portfolio July 17, 2024 Via InvestorPlace Better GLP-1 Biotech Stock: Altimmune vs. Viking Therapeutics July 10, 2024 Via The Motley Fool Eli Lilly Stock Leads in GLP-1 Race with its Triple Agonist Drug July 09, 2024 Via MarketBeat 7 Bullish Stock Picks With the Potential to Turn $5K Into $50K July 09, 2024 Via InvestorPlace The 7 Best Under $10 Stocks to Buy in July 2024 July 06, 2024 Via InvestorPlace MarketBeat Week in Review – 7/1 - 7/5 July 06, 2024 Via MarketBeat Topics Economy Exposures Interest Rates Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Intel, Harbor Diversified, Altimmune, and Sprout Social and Encourages Investors to Contact the Firm July 04, 2024 From Bragar Eagel & Squire Via GlobeNewswire SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune July 04, 2024 From Faruqi & Faruqi LLP Via GlobeNewswire ALTIMMUNE DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Altimmune, Inc. and Encourages Investors to Contact the Firm July 03, 2024 From Bragar Eagel & Squire Via GlobeNewswire The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Altimmune, Inc. (ALT) July 03, 2024 From Law Offices of Frank R. Cruz Via Business Wire Altimmune Stock: Is Its GLP-1 Drug the Next Ozempic Killer? July 03, 2024 Via MarketBeat Exposures Product Safety Pfizer Stock is Ready to Stage a Turnaround on GLP-1 Hopes July 02, 2024 Via MarketBeat Eli Lilly Stock Up: GLP-1 Zepbound Targets Sleep Apnea Market July 01, 2024 Via MarketBeat Exposures Product Safety ALTIMMUNE, INC. (NASDAQ: ALT) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Altimmune, Inc. Investors of Upcoming Deadline July 01, 2024 From Bernstein Liebhard LLP Via GlobeNewswire Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Intel, AXT, Harbor Diversified, and Altimmune and Encourages Investors to Contact the Firm June 30, 2024 From Bragar Eagel & Squire Via GlobeNewswire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.